FOXP3 and neoplasm: A pan-cancer meta-analysis revealed the heterogeneity of the prognostic roles of FoxP3s among tumor sites and the antitumor role of FoxP3 in HNSCC (OR, 0.69; 95% CI, 0.50~0.95; p < 0.05).